Literature DB >> 3516430

Pharmacokinetics of high-dose intravenous melphalan in children and adults with forced diuresis. Report in 26 cases.

C Ardiet, B Tranchand, P Biron, P Rebattu, T Philip.   

Abstract

The pharmacokinetic parameters of the alkylating agent melphalan were determined in 15 children and 11 adults with advanced malignant solid tumors. High IV bolus doses of 140 mg/m2 were given under standard hyperhydration conditions and followed by autologous bone marrow grafting. In all cases the time-concentration curves could be best fitted to a biexponential pattern. A high scattering of drug concentrations was observed in our patients, the disposition half-lives ranging in the whole group from 17.8 to 71.2 min. The areas under the curves also showed a wide variation, ranging from 175 to 682 mg 1(-1) min-1. In all patients, melphalan levels in plasma were unmeasurable at 8 h or earlier, indicating that bone marrow can be safely reinfused at that time. No difference was apparent between children and adults regarding the drug pharmacokinetics. In each of 11 cerebrospinal fluid samples drawn 45-150 min after melphalan administration, drug levels were unmeasurable.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3516430     DOI: 10.1007/bf00293997

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  13 in total

1.  PHARM--an interactive graphic program for individual and population pharmacokinetic parameter estimation.

Authors:  R Gomeni
Journal:  Comput Biol Med       Date:  1984       Impact factor: 4.589

2.  The pharmacokinetics of melphalan in patients with multiple myeloma: an intravenous/oral study using a conventional dose regimen.

Authors:  K W Woodhouse; P Hamilton; A Lennard; M D Rawlins
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

3.  Pharmaco-kinetics of melphalan following oral or intravenous administration in patients with malignant disease.

Authors:  M H Tattersall; M Jarman; E S Newlands; L Holyhead; R A Milstead; A Weinberg
Journal:  Eur J Cancer       Date:  1978-05       Impact factor: 9.162

4.  Pharmacology of intravenous melphalan in patients with multiple myeloma.

Authors:  L Brox; L Birkett; A Belch
Journal:  Cancer Treat Rev       Date:  1979-06       Impact factor: 12.111

5.  Comparison of the fed and fasting states on the absorption of melphalan in multiple myeloma.

Authors:  A G Bosanquet; E D Gilby
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

6.  High-pressure liquid chromatographic analysis of melphalan in plasma.

Authors:  S Y Chang; D S Alberts; L R Melnick; P D Walson; S E Salmon
Journal:  J Pharm Sci       Date:  1978-05       Impact factor: 3.534

7.  Pharmacokinetics of high-dose melphalan in children and adults.

Authors:  A Gouyette; O Hartmann; J L Pico
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

8.  Quantitation by gas chromatography-chemical ionization-mass spectrometry of phenylalanine mustard in plasma of patients.

Authors:  S L Pallante; C Fenselau; R G Mennel; R B Brundrett; M Appler; N B Rosenshein; M Colvin
Journal:  Cancer Res       Date:  1980-07       Impact factor: 12.701

9.  Plasma melphalan and prednisolone concentrations during oral therapy for multiple myeloma.

Authors:  I A Taha; R A Ahmad; H Gray; C I Roberts; H J Rogers
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

10.  Marrow autotransplantation accelerates haematological recovery in patients with malignant melanoma treated with high-dose melphalan.

Authors:  T J McElwain; D W Hedley; G Burton; H M Clink; M Y Gordon; M Jarman; C A Juttner; J L Millar; R A Milsted; G Prentice; I E Smith; D Spence; M Woods
Journal:  Br J Cancer       Date:  1979-07       Impact factor: 7.640

View more
  16 in total

1.  High-dose melphalan dosage adjustment: possibility of using a test-dose.

Authors:  B Tranchand; Y D Ploin; M P Minuit; C Sapet; P Biron; T Philip; C Ardiet
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Population Pharmacokinetics and Optimal Sampling Strategy for Model-Based Precision Dosing of Melphalan in Patients Undergoing Hematopoietic Stem Cell Transplantation.

Authors:  Kana Mizuno; Min Dong; Tsuyoshi Fukuda; Sharat Chandra; Parinda A Mehta; Scott McConnell; Elias J Anaissie; Alexander A Vinks
Journal:  Clin Pharmacokinet       Date:  2018-05       Impact factor: 6.447

3.  Survival of twenty-two months in a patient with primary plasma cell leukaemia treated with melphalan and prednisolone.

Authors:  J D Walker; R S Kaczmarski
Journal:  Postgrad Med J       Date:  1988-03       Impact factor: 2.401

4.  The pharmacokinetics of melphalan during intermittent therapy of multiple myeloma.

Authors:  U Loos; E Musch; M Engel; J H Hartlapp; E Hügl; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

5.  A sensitive high-performance liquid chromatographic assay for melphalan and its hydrolysis products in blood and plasma.

Authors:  H K Osterheld; E Musch; G E von Unruh; U Loos; H Rauschecker; B J Mühlenbruch
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

6.  Population pharmacokinetics of melphalan in paediatric blood or marrow transplant recipients.

Authors:  Christa E Nath; Peter J Shaw; Kay Montgomery; John W Earl
Journal:  Br J Clin Pharmacol       Date:  2007-02-23       Impact factor: 4.335

7.  Melphalan pharmacokinetics in children with malignant disease: influence of body weight, renal function, carboplatin therapy and total body irradiation.

Authors:  Christa E Nath; Peter J Shaw; Kay Montgomery; John W Earl
Journal:  Br J Clin Pharmacol       Date:  2005-03       Impact factor: 4.335

8.  Renal clearance and protein binding of melphalan in patients with cancer.

Authors:  P A Reece; H S Hill; R M Green; R G Morris; B M Dale; D Kotasek; R E Sage
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

9.  Melphalan concentration dependent plasma protein binding in healthy humans and rats.

Authors:  N H Greig; D J Sweeney; S I Rapoport
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 10.  Fifty years of melphalan use in hematopoietic stem cell transplantation.

Authors:  Ulas D Bayraktar; Qaiser Bashir; Muzaffar Qazilbash; Richard E Champlin; Stefan O Ciurea
Journal:  Biol Blood Marrow Transplant       Date:  2012-08-24       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.